Clinical Trials

125 enrolled 18 charts 2 FDA

LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02684292 2026-02-18

MK-3475-204

304 enrolled 3 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Hodgkin Disease

NCT02972840 2026-02-18

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

635 enrolled 3 FDA

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT03332017 2026-02-18

ROSEWOOD

217 enrolled 23 charts 2 FDA

Phase 2 Active not recruiting

Lymphoma, Follicular

NCT02213926 2026-02-10

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

124 enrolled 10 charts 2 FDA

Lymphoma, Mantle-Cell

NCT02970318 2026-02-06

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

310 enrolled 18 charts 2 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03274492 2026-02-06

POLARIX

1,000 enrolled 2 FDA

LymphoidOther hematologic neoplasmSarcoma

Lymphoma, Large B-Cell, Diffuse

NCT03740529 2026-01-27

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

Phase 1/2 Completed

803 enrolled 4 FDA

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT03105336 2025-12-23

ZUMA-5

159 enrolled 27 charts 2 FDA

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT04680052 2025-12-22

InMIND

654 enrolled 40 charts 3 FDA

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT03391466 2025-12-01

ZUMA-7

359 enrolled 27 charts 1 FDA

Lymphoma, Large B-Cell, Diffuse

NCT03589326 2025-11-26

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

245 enrolled 15 charts 2 FDA

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

NCT04067336 2025-11-10

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Phase 1/2 Recruiting

263 enrolled 3 FDA

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02242942 2025-11-06

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

445 enrolled 22 charts 2 FDA

Phase 2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04245839 2025-11-05

TRANSCEND FL

276 enrolled 5 FDA

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT03568461 2025-10-07

ELARA

98 enrolled 9 charts 2 FDA

Lymphoma, Follicular, Recurrence

NCT02227251 2025-10-01

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2 Recruiting

244 enrolled 3 FDA

Lymphoma, Large B-Cell, Diffuse

NCT02500407 2025-09-12

A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Phase 1/2 Completed

713 enrolled 2 FDA

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02475681 2025-08-27

ElevateTN

535 enrolled 19 charts 2 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03575351 2025-08-03

TRANSFORM

184 enrolled 30 charts 2 FDA

Lymphoma, Non-Hodgkin, Recurrence

NCT05409066 2025-07-28

EPCORE FL-1

549 enrolled 5 FDA

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT01996865 2025-07-10

MAGNIFY

503 enrolled 18 charts 2 FDA

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03580655 2025-04-30

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

LymphoidMyeloidOther hematologic neoplasm

107 enrolled 2 FDA

Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT04666038 2025-04-20

BRUIN CLL-321

238 enrolled 17 charts 3 FDA

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT03734016 2025-03-30

ALPINE

652 enrolled 27 charts 2 FDA

Phase 1 Active not recruiting

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03212404 2025-02-03

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

272 enrolled 3 FDA

DermatologicGenitourinaryGynecologicHead & NeckLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Neoplasms, Skin Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Carcinoma, Small Cell

NCT01121588 2025-01-23

Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)

Phase 1 Terminated

44 enrolled 22 charts 2 FDA

CNSLymphoid

Lymphoma, Neoplasms, Neuroblastoma

NCT03836261 2024-12-27

AMPLIFY

984 enrolled 3 FDA

Leukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03053440 2024-10-26

ASPEN

201 enrolled 19 charts 2 FDA

Waldenstrom Macroglobulinemia

NCT03206970 2024-10-26

Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

86 enrolled 16 charts 2 FDA

Lymphoma, Mantle-Cell

NCT03846427 2024-10-26

MAGNOLIA

68 enrolled 28 charts 2 FDA

Lymphoma, B-Cell, Marginal Zone

NCT02631044 2024-06-27

Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

Phase 1 Completed

387 enrolled 4 FDA

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02393859 2024-05-29

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

111 enrolled 23 charts 2 FDA

Immunoproliferative Disorders, Lymphoproliferative Disorders, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02000427 2024-05-28

Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia

45 enrolled 24 charts 2 FDA

Leukemia, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01728805 2024-04-25

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

372 enrolled 14 charts 2 FDA

DermatologicLymphoid

Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT02445248 2024-04-18

JULIET

115 enrolled 22 charts 2 FDA

400 enrolled 22 charts 3 FDA

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT01897571 2024-03-26

Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL

Phase 1/2 Completed

405 enrolled 27 charts 2 FDA

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02013167 2024-03-05

Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Phase 3 Terminated

Leukemia, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02435849 2024-02-13

ELIANA

80 enrolled 39 charts 1 FDA

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03483103 2023-12-20

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)

74 enrolled 43 charts 2 FDA

229 enrolled 17 charts 4 FDA

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04145531 2023-11-18

An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)

Phase 2/3 Completed

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02399085 2023-10-23

L-MIND

81 enrolled 23 charts 3 FDA